scholarly journals Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo

2018 ◽  
Vol Volume 11 ◽  
pp. 6705-6722 ◽  
Author(s):  
Min Chen ◽  
Jian Lu ◽  
Wei Wei ◽  
Ying Lv ◽  
Xiaoqi Zhang ◽  
...  
Keyword(s):  
Multidrug Resistance ◽  
Signaling Pathway ◽  
Gastric Adenocarcinoma ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Adenocarcinoma Cells ◽  
Human Gastric Adenocarcinoma

scholarly journals The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo

2018 ◽  
Vol 108 ◽  
pp. 60-64 ◽  
Author(s):  
Miao Yan ◽  
Zhu-feng Wu ◽  
Dan Tang ◽  
Feng Wang ◽  
Yi-wen Xiao ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
The Impact

Proton pump inhibitors as a possible cause of vitiligo: an in vivo and in vitro study

2013 ◽  
Vol 28 (11) ◽  
pp. 1475-1479 ◽  
Author(s):  
J.M. Shin ◽  
J.Y. Lee ◽  
D.Y. Lee ◽  
T.Y. Yoon ◽  
J.C. Lee ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
In Vitro Study ◽  
Vitro Study ◽  
Possible Cause

The deleterious association between proton pump inhibitors and prostate cancer specific death.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 309-309
Author(s):  
Hanan Goldberg ◽  
Faizan Moshin ◽  
Refik Saskin ◽  
Girish S. Kulkarni ◽  
Alejandro Berlin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cox Regression ◽  
Population Based ◽  
Study Data ◽  
History Of ◽  
Time Dependent Covariates

309 Background: Proton pump inhibitors (PPIs) are a commonly prescribed class of medications. Although in-vitro and in-vivo data have shown PPIs to have anti-tumor effects, more recent studies suggest an increased cancer risk in several solid organs. Pantoprazole, a commonly prescribed PPI, has been shown to harbor a protective effect in human prostate cancer (PCa) cells. We aimed to investigate the effect of pantoprazole and other PPIs on PCa-specific death and additional PCa outcomes. Methods: In this retrospective, population-based cohort study, data were incorporated from the Institute for Clinical and Evaluative Sciences to identify all men aged 66 and above with a history of a single negative prostate biopsy between 1994 and 2016. We used multivariable Cox regression models with time-dependent covariates, to assess the effect of PPIs on PCa diagnosis, androgen deprivation therapy (ADT) use, and PCa-specific death. All models included other medications with a putative effect on PCa. All models were adjusted for age, rurality, comorbidity, and year of patient study inclusion. Results: Overall, 21,512 men were included, with a mean follow-up time of 8.06 years (SD 5.44 years). A total of 10,999 patients (51.1%) used a PPI. A total of 5,187 patients (24.1%) were diagnosed with PCa, 2,043 patients (9.5%) were treated with ADT, and 805 patients (3.7%) died from PCa. Pantoprazole was associated with a 3.0% (95% CI 0.3%-6,0%) increased rate of being treated with ADT for every six months of cumulative use, while any use of all other PPIs was associated with a 39.0% (95% CI 18.0%-64.0%) increased PCa-specific mortality. No significant association was found with PCa diagnosis. Conclusions: Upon validation of the potentially negative association of PPIs with PCa outcomes, the expansive use of PPIs may need to be reassessed, especially in PCa patients.

In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors

2015 ◽  
Vol 29 (6) ◽  
pp. 604-614 ◽  
Author(s):  
Edouard Ollier ◽  
Sophie Hodin ◽  
Thierry Basset ◽  
Sandrine Accassat ◽  
Laurent Bertoletti ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
In Vivo Evaluation ◽  
Drug Drug Interaction

scholarly journals In vitro and in vivo Protection against Indomethacin-Induced Small Intestinal Injury by Proton Pump Inhibitors, Acid Pump Antagonists, or Indomethacin-Phosphatidylcholine

Digestion ◽  
2012 ◽  
Vol 86 (2) ◽  
pp. 171-177 ◽  
Author(s):  
Yun Jeong Lim ◽  
Tri M. Phan ◽  
Elizabeth J. Dial ◽  
David Y. Graham ◽  
Lenard M. Lichtenberger
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Intestinal Injury ◽  
Small Intestinal Injury ◽  
Small Intestinal

Wireless Portable Evaluation Platform for Photodynamic Therapy: In vitro Assays on Human Gastric Adenocarcinoma Cells

2020 ◽  
Vol 20 (23) ◽  
pp. 13950-13958
Author(s):  
Rodrigo Henrique Gounella ◽  
Ilaiali Souza Leite ◽  
Natalia Mayumi Inada ◽  
Joao Paulo P. do Carmo
Keyword(s):  
Photodynamic Therapy ◽  
Gastric Adenocarcinoma ◽  
In Vitro Assays ◽  
Adenocarcinoma Cells ◽  
Human Gastric Adenocarcinoma ◽  
Evaluation Platform

scholarly journals The Potential Therapeutic Role of Proton Pump Inhibitors in COVID-19: Hypotheses Based on Existing Evidences

Drug Research ◽  
2020 ◽  
Vol 70 (10) ◽  
pp. 484-488
Author(s):  
Avik Ray ◽  
Swati Sharma ◽  
Balakrishnan Sadasivam
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Treatment Options ◽  
Therapeutic Effects ◽  
Randomized Controlled ◽  
Therapeutic Uses ◽  
Potential Therapeutic Role

AbstractAlthough the major therapeutic uses of the proton pump inhibitors are in gastric-acid related diseases, evidences are suggestive of a pleiotropic nature of the compounds. We comment on the probable pathways and cellular machineries via which proton pump inhibitors could show beneficial therapeutic effects against SARS-CoV-2 based on the existing evidences. Proton pump inhibitors have shown antiviral potencies in various in vivo and in vitro studies. Some of the major possible ways through which they can act against SARS-CoV-2 are by exerting anti-inflammatory and anti-fibrotic effects, via vacuolar ATPase pumps leading to raised endolysosomal pH and by targeting endosomal complexes. The current pandemic has put forward a challenge to find treatment options. Although the potential roles of proton pump inhibitors against SARS-CoV-2 have been discussed in recent publications, the clinical evidences for their real-world effectiveness do not point towards a beneficial effect clearly yet. We suggest that although proton pump inhibitors should strongly be considered as potential therapeutic options for COVID-19, larger studies in the form of randomized controlled trials would be required to arrive at a definite conclusion.

Sign in / Sign up

Export Citation Format

Share Document